1文献来源
Tetsuya M, Satoshi M, Yasushi Y, et al. Gefitinib versus Cisplatin plus Docetaxel in patients with non-small-cell lung cancer harbouring mutations of theepidermal growth factor receptor （WJTOG3405） ： Ano...1文献来源
Tetsuya M, Satoshi M, Yasushi Y, et al. Gefitinib versus Cisplatin plus Docetaxel in patients with non-small-cell lung cancer harbouring mutations of theepidermal growth factor receptor （WJTOG3405） ： Anopen label, randomised phase 3 trial [J]. LancetOncol,2010, 11（2） ： 121-125.展开更多
1文献来源
Douillard JY, Shepherd FA, Hirsh V, et al.Molecular predictors of outcome with Gefitinib andDocetaxel in previously treated non-small-cell lungcancer ： Data from the randomized phase Ⅲ INTEREST trial [J]...1文献来源
Douillard JY, Shepherd FA, Hirsh V, et al.Molecular predictors of outcome with Gefitinib andDocetaxel in previously treated non-small-cell lungcancer ： Data from the randomized phase Ⅲ INTEREST trial [J]. J Clin Oncol, 2010,28 （5）：744-752.展开更多
1文献来源
Makoto M, Akira I, Kunihiko K, et al. Gefitinib or chemotherapy for non-small cell lung cancerwith mutated EGFR [J]. N Engl J Med, 2010, 362（25） ： 2380-2388.
文摘1文献来源
Tetsuya M, Satoshi M, Yasushi Y, et al. Gefitinib versus Cisplatin plus Docetaxel in patients with non-small-cell lung cancer harbouring mutations of theepidermal growth factor receptor （WJTOG3405） ： Anopen label, randomised phase 3 trial [J]. LancetOncol,2010, 11（2） ： 121-125.
文摘1文献来源
Douillard JY, Shepherd FA, Hirsh V, et al.Molecular predictors of outcome with Gefitinib andDocetaxel in previously treated non-small-cell lungcancer ： Data from the randomized phase Ⅲ INTEREST trial [J]. J Clin Oncol, 2010,28 （5）：744-752.
文摘1文献来源
Makoto M, Akira I, Kunihiko K, et al. Gefitinib or chemotherapy for non-small cell lung cancerwith mutated EGFR [J]. N Engl J Med, 2010, 362（25） ： 2380-2388.
